Get the Stockscreener App
3.32
0.30%
0.010
Sight Sciences Inc stock is traded at $3.32, with a volume of 250.79K.
It is up +0.30% in the last 24 hours and down -16.79% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
See More
Previous Close:
$3.31
Open:
$3.28
24h Volume:
250.79K
Relative Volume:
1.16
Market Cap:
$167.32M
Revenue:
$81.06M
Net Income/Loss:
$-55.55M
P/E Ratio:
-2.9123
EPS:
-1.14
Net Cash Flow:
$-47.98M
1W Performance:
-7.26%
1M Performance:
-16.79%
6M Performance:
-48.37%
1Y Performance:
-40.18%
1-Day Range:
$3.20
$3.39
1-Week Range:
$3.20
$3.59
52-Week Range:
$3.20
$8.45
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
3.32 | 167.32M | 81.06M | -55.55M | -47.98M | -1.14 |
|
ABT
Abbott Laboratories
|
114.25 | 198.16B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.95 | 141.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
364.10 | 138.80B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
82.68 | 106.02B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.15 | 43.73B | 6.60B | 4.16B | 490.10M | 6.93 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
Sight sciences chief legal officer Jeremy Hayden sells $5,898 in stock - Investing.com
OMNI Surgical System shows promise in glaucoma care By Investing.com - Investing.com South Africa
Sight Sciences stock hits 52-week low at $3.29 amid market challenges - Investing.com Canada
OMNI Surgical System shows promise in glaucoma care - Investing.com India
Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma - The Manila Times
Sight Sciences Announces Real-World 36-Month Study - GlobeNewswire
Sight Sciences (SGHT) Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System - StreetInsider.com
Sight Sciences' OMNI System Shows Breakthrough 3-Year Success in Landmark Glaucoma Study - StockTitan
Sight Sciences CTO David Badawi sells $10,956 in stock By Investing.com - Investing.com Nigeria
Sight sciences CEO Paul Badawi sells $44,012 in stock - Investing.com India
Sight sciences chief legal officer sells shares worth $17,131 - Investing.com India
Sight sciences chief legal officer sells shares worth $17,131 By Investing.com - Investing.com Nigeria
Sight sciences CFO Alison Bauerlein sells shares worth $35,579 By Investing.com - Investing.com Nigeria
Sight sciences CEO Paul Badawi sells $44,012 in stock By Investing.com - Investing.com South Africa
Insider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) CEO Sells 12,236 Shares of Stock - MarketBeat
Insider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells 3,111 Shares of Stock - MarketBeat
Sight sciences CFO Alison Bauerlein sells shares worth $35,579 - Investing.com India
Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $17,121.28 in Stock - MarketBeat
Sight Sciences CTO David Badawi sells $10,956 in stock - Investing.com India
Geode Capital Management LLC Raises Position in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Barclays PLC Increases Stock Holdings in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences, Inc. (NASDAQ:SGHT) Receives $5.12 Consensus Target Price from Brokerages - MarketBeat
State Street Corp Increases Stock Position in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences, Inc. (NASDAQ:SGHT) Given Average Rating of “Hold” by Brokerages - Defense World
Sight Sciences Announces the Results of a Budget Impact - GlobeNewswire
Sight Sciences' TearCare System Shows Major Cost Savings Over Traditional Dry Eye Treatments in New Study - StockTitan
Citigroup Has Lowered Expectations for Sight Sciences (NASDAQ:SGHT) Stock Price - Defense World
Sight Sciences secures $5 million in additional loan funding - Investing.com
Sight Sciences secures $5 million in additional loan funding By Investing.com - Investing.com UK
Where Sight Sciences Stands With Analysts - Benzinga
Sight sciences EVP Manohar Raheja acquires $19,250 in stock - Investing.com
Sight sciences EVP Manohar Raheja acquires $19,250 in stock By Investing.com - Investing.com UK
Sight Sciences (NASDAQ:SGHT) Research Coverage Started at UBS Group - Defense World
Sight Sciences, Inc. (NASDAQ:SGHT) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Sight Sciences (NASDAQ:SGHT) Coverage Initiated at UBS Group - MarketBeat
Sight Sciences initiated with a Buy at UBS - Yahoo Finance
UBS Initiates Coverage of Sight Sciences (SGHT) with Buy Recommendation - Nasdaq
UBS starts Sight Sciences stock coverage, forecasts strong sales growth by 2026 - Investing.com
UBS Starts Sight Sciences Inc. (SGHT) at Buy - StreetInsider.com
Sight sciences EVP Manohar Raheja buys $13,132 in stock By Investing.com - Investing.com Canada
Sight sciences EVP Manohar Raheja buys $13,132 in stock - Investing.com
Sight sciences EVP Manohar Raheja acquires $18,440 in stock By Investing.com - Investing.com Canada
Sight sciences EVP Manohar Raheja acquires $18,440 in stock - Investing.com
Millrace Asset Group Inc. Makes New Investment in Sight Sciences, Inc. (NASDAQ:SGHT) - MarketBeat
GSA Capital Partners LLP Invests $136,000 in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Nano Dimension Leads 3 US Penny Stocks To Consider - Simply Wall St
Independent Chairman Of Sight Sciences Sold 25% Of Their Shares - Simply Wall St
Hedge Fund and Insider Trading News: Ken Griffin, Bridgewater Associates, AQR Capital Management, Brookfield Asset Management, Sight Sciences Inc (SGHT), Royal Caribbean Cruises Ltd (RCL), and More - Insider Monkey
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):